Search Site
Home >> Signaling Pathways >> TGF-β / Smad Signaling >> Bcr-Abl >> Dasatinib (BMS-354825)
Related Products
Dasatinib (BMS-354825)Src and BCR-Abl inhibitor

Dasatinib (BMS-354825)

Catalog No. A3017
Size Price Stock Qty
10mM (in 1mL DMSO) $55.00 In stock
100mg $50.00 In stock
500mg $95.00 In stock

Tel: +1-832-696-8203


Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

Dasatinib (anhydrous)

Related Biological Data

293T cells were transfected with wild type c-Abl, or the gatekeeper mutation for c-Abl T315I. Transfected cells were untreated or treated with 5mM H2O2 for 10 min with or without pretreatment with 20 nM dasatinib for 30min. Whole cell lysates were resolved using SDS-PAGE and analyzed for PKCδpY64, pY155, and pY311. An asterisk denotes the band representing PKCδpY155. Blots were stripped and probed for total PKCδ, total c-Src, total c-Abl, andactin.

Biological Activity

Targets Abl Src c-Kit (WT)/c-Kit (D816V)      
IC50 0.6 nM 0.8 nM 79 nM/37 nM      


Cell experiment: [1]

Cell lines

DU-145 and LNCaP cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

100 nM, 6 hours for inhibiting FAK phosphorylation 24 hours for decreasing cell-to-cell contact


Dasatinib almost totally abolished the levels of p-FAK at Tyr576/577 in DU-145 cells, whereas p-FAK was not detected in LNCaP cells even though both cell lines expressed similar levels of total FAK protein. Treatment with 100 nmol/L dasatinib for 24 hours had no effect on cell viability and total cell numbers, although partial inhibition of cell proliferation due to G1 arrest was observed at 48 and 72 hours. Besides, there was a substantial loss of cell-to-cell contact in DU-145 cells. This effect may be related to the decrease in levels of p-FAK and p-p130CAS.

Animal experiment: [2]

Animal models

Pdx1-Cre, Z/EGFP, LSL-Kras G12D/+, LSL-Trp53R172H/+ mice

Dosage form

Oral administration, 10 mg/kg, daily


There was no significant difference in survival between the different treatment groups. The median survival of vehicle-treated animals was 131 days compared with 127 days and 130 days for animals treated with dasatinib from 6 weeks and 10 weeks of age, respectively. Analysis of tumor burden in the mice showed that all mice had invasive PDAC; however, the number of mice with metastases was reduced significantly in dasatinib-treated animals. The incidence of metastases was 61.1% in vehicle-treated animals compared with 26.7% in mice treated with dasatinib from 6 weeks and 23.1% in mice treated with dasatinib from 10 weeks.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Nam S, Kim D, Cheng J Q, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer research, 2005, 65(20): 9185-9189.

[2] Morton J P, Karim S A, Graham K, et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology, 2010, 139(1): 292-303.

Dasatinib (BMS-354825) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Dasatinib (BMS-354825) Molarity Calculator



Chemical Properties

Cas No. 302962-49-8 SDF Download SDF
Synonyms Sprycel,dasatinibum,Dasatinib,BMS-354825, BMS354825, BMS 354825
Chemical Name N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
Canonical SMILES CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)N4CCN(CC4)CCO)C
Formula C22H26ClN7O2S M.Wt 488.01
Solubility Soluble in DMSO > 10 mM Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Research Update

1. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev. 2014 Mar;40(2):285-92. doi: 10.1016/j.ctrv.2013.09.004. Epub 2013 Sep 17.
Randomized trials have been conducted to compare the effects of dasatinib, nilotinib and imatinib in the treatment of newly diagnosed chronic myrloid leukemia in the chronic phase.
2. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec;14(13):1307-16. doi: 10.1016/S1470-2045(13)70479-0. Epub 2013 Nov 8.
Dasatinib is an inhibitor of tyrosine kinase including Src kinases that exhibits antitumor activity, affects osteoclasts and synergize with docetaxel. The efficacy of dasatinib alone or with docetaxel has been assessed in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
3. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol. 2013 Dec;139(12):1971-84. doi: 10.1007/s00432-013-1488-z. Epub 2013 Aug 13.
Dasatinib is a dual Abl/Src TKI that inhibits BCR-ABL with relatively greater potency and show potential immunomodulatory effects. Since it’s been approved to treat CML patients, the development of dasatinib is reviewed.
4. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. J Pathol. 2013 Aug;230(4):430-40. doi: 10.1002/path.4202.
Daily oral administration of dasatinib, an inhibitor of Src family kinases, to mice with breast cancer delays tumor onset and increases overall survival with the occurrence of squamous metaplasis accompanied by down-regulation of ErbB-2 and up-regulation of E-cadherin and β-catenin. Additionally, dasatinib inhibited both migration and invasion of tumour-derived cell lines in vitro.
5. Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report. J Clin Pharm Ther. 2014 Feb;39(1):102-5. doi: 10.1111/jcpt.12107. Epub 2013 Nov 5.
Dasatinib is an inhibitor of multiple tyrosine kinases that are used to treat CML and ALL. Although renal failure is a rare side effect of dasatinib, a patient with imatinib-resistant CML has developed both PE and ARF after receiving dastinib.


Dasatinib is a small-molecule inhibitor of both the Src and Bcr-Abl tyrosine kinases with IC50 values of 0.5 nM and 1 nM.  The oncogenic tyrosine kinase Bcr-Abl, plays a critical role in the pathogenesis of CML (chronic myelogenous leukemia). In most CML patients, the kinase domain of Bcr-Abl have mutations that interfere with binding to the first Abl kinase inhibitor, but Dasatinib bind more efficiently to these Abl kinase mutations and thus more effective than imatinib in inhibiting the proliferation cells with wild-type Bcr-Abl or Bcr-Abl mutants.

1. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. S Nam, D Kim, JQ Cheng, S Zhang, JH Lee, R Buettner. Cancer Research. 2005
2. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. L Song, M Morris, T Bagui, FY Lee, R Jove, EB Haura . Cancer Research. 2006